Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has issued an announcement.
AIM Vaccine Co., Ltd. has announced a forthcoming board meeting scheduled for March 28, 2025, to discuss and approve the annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend payment and address other business matters, potentially impacting the company’s financial strategies and stakeholder interests.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the vaccine industry. It focuses on the development and production of vaccines, serving a critical role in public health by providing immunization products.
YTD Price Performance: -36.32%
Average Trading Volume: 6,319,249
Technical Sentiment Consensus Rating: Buy
Find detailed analytics on 6660 stock on TipRanks’ Stock Analysis page.